LSALT peptide: meta-analysis of COVID-19 studies

All studies Mortality Hospitalization Serious outcomes RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−407%

Mortality (1)−407%

Hospitalization (1)−7%

RCTs (1)−407%

Late (1)−407%

00.511.5+

← LSALT peptide
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

LSALT peptide COVID-19 studies (1 unreported RCT)

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Somayaji (DB RCT)−407%5.07 · 0.25–101death2/300/31 Fowler (RCT)n/a< NOT REPORTED >580 (est. total)CATCO>2 years late

Late treatment−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →

c19early.org

October 2026

LSALT peptide COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Somayaji (DB RCT)−407%5.07 · 0.25–1012/300/31

Late treatment−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →

c19early.org

October 2026

LSALT peptide COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Somayaji (DB RCT)−7%1.07 · 0.80–1.43hosp. time30 (n)31 (n)

Late treatment−7%1.07 · 0.80–1.4330 (n)31 (n)7% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.65

All studies−7%1.07 · 0.80–1.4330 (n)31 (n)7% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6500.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →

c19early.org

October 2026

LSALT peptide COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Somayaji (DB RCT)−407%5.07 · 0.25–101death2/300/31

Late treatment−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →

c19early.org

October 2026

LSALT peptide COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Somayaji (DB RCT)−407%5.07 · 0.25–101death2/300/31 Fowler (RCT)n/a< NOT REPORTED >580 (est. total)CATCO>2 years late

Late treatment−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →

c19early.org

October 2026

LSALT peptide COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Somayaji (DB RCT)−407%5.07 · 0.25–1012/300/31

Late treatment−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →

c19early.org

October 2026

LSALT peptide COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Somayaji (DB RCT)−407%5.07 · 0.25–101death2/300/31

Late treatment−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−407%5.07 · 0.25–1012/300/31407% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →

c19early.org

October 2026

LSALT peptide COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Somayaji (DB RCT)−407%5.07 · 0.25–101death2/300/31 Somayaji (DB RCT)−203%3.03 · 0.13–71.66death1/300/31 Somayaji (DB RCT)−3%1.03 · 0.16–6.87ARDS2/302/31 Somayaji (DB RCT)−7%1.07 · 0.80–1.43hosp. time30 (n)31 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← LSALT peptide
reduces riskLSALT peptide
increases risk →